Skip to content

Fairmount Funds Management LLC

Follow

13F filer, CIK 1802528, WEST CONSHOHOCKEN, PA

Fairmount Funds Management LLC reported $1,594,519,847 across 12 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 97.54% of the portfolio.

Accepted , ingested 13F-HR 0001104659-26-128188

Period
2026-09-30
Reported value
$1.59B
Holdings
12
Top 10 weight
97.54%
New
2
Sold out
2

Stakes and trades reported after 2026-09-30

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • MTRI MENTARI THERAPEUTICS INC: 13D 10,555,507 shares, 19.99% of the class, 13D filed 2026-11-12, 0001193125-26-458677Timeline
    Accepted , ingested
  • TCRT ALAUNOS THERAPEUTICS INC: 13D 858,789 shares, 19.99% of the class, 13D filed 2026-10-15, 0001683168-26-007898Timeline
    Accepted , ingested
  • SYRE SPYRE THERAPEUTICS INC: 13D/A 10,185,961 shares, 9.99% of the class, 13D/A filed 2026-10-09, 0001104659-26-115087Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
KRSAnew+9,103,729$291M
DMRAnew+8,713,000$185M
CBIOadded+853,450$12.5M
ZBIOadded+12,333$333K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
DMRAexited-8,713,000-$227M
APGEexited-298,647-$39.6M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001104659-26-128188, largest first. % of portfolio is the value over $1,594,519,847, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,371,922 shares; 2025Q1: 3,371,922 shares; 2025Q2: 3,371,922 shares; 2025Q3: 3,705,262 shares; 2025Q4: 3,705,262 shares; 2026Q1: 3,705,262 shares; 2026Q2: 3,705,262 shares; 2026Q3: 3,705,262 shares 3,705,262$309M19.35%0Timeline
KRSAKORSANA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 9,103,729 shares 9,103,729$291M18.27%newTimeline
DNTHDIANTHUS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,700,691 shares; 2025Q1: 2,700,691 shares; 2025Q2: 2,707,191 shares; 2025Q3: 3,307,191 shares; 2025Q4: 2,137,191 shares; 2026Q1: 2,537,191 shares; 2026Q2: 2,537,191 shares; 2026Q3: 2,537,191 shares 2,537,191$223M14.01%0Timeline
DMRADAMORA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 8,713,000 shares 8,713,000$185M11.63%newTimeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 6,225,641 shares; 2025Q1: 6,225,641 shares; 2025Q2: 6,225,641 shares; 2025Q3: 9,003,418 shares; 2025Q4: 9,003,418 shares; 2026Q1: 5,503,418 shares; 2026Q2: 5,503,418 shares; 2026Q3: 5,503,418 shares 5,503,418$176M11.05%0Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,445,813 shares; 2025Q1: 3,445,813 shares; 2025Q2: 3,459,913 shares; 2025Q3: 3,459,913 shares; 2025Q4: 3,914,458 shares; 2026Q1: 3,914,458 shares; 2026Q2: 5,090,928 shares; 2026Q3: 5,090,928 shares 5,090,928$105M6.57%0Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,202,798 shares; 2025Q1: 3,202,798 shares; 2025Q2: 3,711,444 shares; 2025Q3: 3,711,444 shares; 2025Q4: 3,711,444 shares; 2026Q1: 1,855,644 shares; 2026Q2: 1,855,644 shares; 2026Q3: 1,855,644 shares 1,855,644$85.1M5.33%0Timeline
JBIOJADE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 3,220,368 shares; 2025Q3: 3,220,368 shares; 2025Q4: 4,553,494 shares; 2026Q1: 4,553,494 shares; 2026Q2: 4,553,494 shares; 2026Q3: 4,553,494 shares 4,553,494$64M4.01%0Timeline
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,892,806 shares; 2025Q1: 1,892,806 shares; 2025Q2: 1,892,806 shares; 2025Q3: 1,892,806 shares; 2025Q4: 2,209,025 shares; 2026Q1: 2,359,025 shares; 2026Q2: 2,359,025 shares; 2026Q3: 2,371,358 shares 2,371,358$64M4.01%+12,333Timeline
CBIOCRESCENT BIOPHARMA INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,387,866 shares; 2025Q3: 1,387,866 shares; 2025Q4: 2,747,866 shares; 2026Q1: 2,747,866 shares; 2026Q2: 2,747,866 shares; 2026Q3: 3,601,316 shares 3,601,316$52.5M3.3%+853,450Timeline
FTHFAETH THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 722,020 shares; 2026Q3: 722,020 shares 722,020$21.5M1.35%0Timeline
IKTINHIBIKASE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 6,125,000 shares; 2025Q1: 6,125,000 shares; 2025Q2: 6,125,000 shares; 2025Q3: 6,125,000 shares; 2025Q4: 8,625,000 shares; 2026Q1: 8,625,000 shares; 2026Q2: 8,625,000 shares; 2026Q3: 8,625,000 shares 8,625,000$17.7M1.11%0Timeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
DMRADAMORA THERAPEUTICS INC8,713,000$227Mshares
APGEAPOGEE THERAPEUTICS INC298,647$39.6Mshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001104659-26-128188 base2026-11-16